Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
about
The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in ratsFurther structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization propertiesUnfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacyTriple reuptake inhibitors: the next generation of antidepressantsReview of pharmacological treatment in mood disorders and future directions for drug development.Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target DrugsTriple uptake inhibitors: therapeutic potential in depression and beyondCurrent investigational drugs for major depressionEffect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring ratEfficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trialsDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsPharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.Triple Reuptake Inhibitors: A Premise and PromiseThe rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression.Rodent models of treatment-resistant depression.Multi-modality: a new approach for the treatment of major depressive disorder.Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands.Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressantsTriple reuptake inhibitors as potential next-generation antidepressants: a new hope?Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes.Catecholamine/Serotonin interactions: systems thinking for brain function and diseaseFlexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.Classical neurotransmitters and neuropeptides involved in major depression: a review.Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.Triple reuptake inhibitors: a patent review (2006 - 2012).An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets.Antidepressant drug development: Focus on triple monoamine reuptake inhibition.Addiction-related effects of DOV 216,303 and cocaine: A comparative study in the mouse.Synthesis, antidepressant activity, and toxicity of the erythro/threo racemates and optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl)hexan-1-ol.Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases.The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
P2860
Q21132285-916E47B9-D25C-4D19-98CD-D98CFB58F734Q24603864-4427EF4E-3664-43AD-910C-A38F8A442A00Q24633511-EF6ACC43-0998-4901-B015-8400B8C50EFCQ24658095-F824772B-2E08-4FFA-8427-D9C5918EFC08Q24658248-414ED240-AC64-4179-A8B6-9543731DD4E3Q26853509-CC4E9895-37C8-43A0-933D-2E1E926D442DQ28074736-4D22C2D4-61A5-462F-9AED-2EABF72C0F8AQ28241732-BC572384-B02E-4DB9-BBBA-B1925651673EQ28244223-4E5FF7CE-B02A-4E5F-9B29-944C3B2307BDQ28251435-578FD7BB-B5B9-4CF0-A04D-A4ACA55E2595Q28252146-034DFE21-F42A-4F54-B221-B5C8850E8A0DQ28305100-CC09B4A0-D6C3-40C9-B88A-AC28D716F396Q28545209-882D14F3-525C-42CB-A7C4-BAC047B0F202Q28972234-88803EAF-1895-45F9-8182-09F89845645BQ34644369-4A4EC7C8-04DE-4EC6-BEE7-427090653BD7Q35054544-00C082D0-E3CD-4C7C-BFF7-5A31F3A96156Q35120152-3AE6414D-B413-49A9-B956-EC53ADA46744Q35580361-41125762-9F9F-45BB-8751-61F13E874FF8Q36896252-7DE642B6-1238-4328-9EBA-4183F2EFDDAAQ37020345-C69B244B-8593-465D-9F89-E1FC7B9F5D46Q37071538-7FEF94C6-EAC2-4736-BCBC-3BDF9FA06CBBQ37158450-5BCB6888-B349-4889-9EEA-BE16728D7667Q37460264-6231B228-FE55-4C8F-B859-AD33059E7FE2Q37518766-3301CBA3-A2B0-488C-8157-1C126A1AE3F4Q37552410-318AC3C0-A723-4B29-A180-27C57ED8FEF3Q37768172-41F4084C-C089-409D-BDB7-628D61538623Q37891098-4542D7BB-47A5-4227-8D54-31E30747D5F2Q38167327-808819E3-C144-4795-A3D9-5069CB9AC096Q38167857-CA497B15-8569-4735-90B7-D959817A57DCQ38260259-19B34477-9B67-41CB-A9AF-9E9CA54C28B3Q39299851-BA196110-CB41-4B18-BE06-802777B1B261Q44519902-E7D94299-DC30-4C6E-847A-64453641C9B2Q47720903-69F2F110-CAC0-42E5-B3A6-1F6EF27F4D72Q48371652-2BA27DF0-FA99-4930-A33D-BE013F8AD3FA
P2860
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
@ast
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
@en
type
label
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
@ast
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
@en
prefLabel
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
@ast
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
@en
P2093
P2860
P1476
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
@en
P2093
Anthony Basile
Arnold Lippa
Joseph Tizzano
Pal Czobor
Phil Skolnick
Philip Krieter
P2860
P304
P356
10.1111/J.1527-3458.2006.00123.X
P50
P577
2006-01-01T00:00:00Z